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Abstract Clinical biomarkers of cardiac function could also
be monitored postmortem. Among the natriuretic peptides,
the aminoterminal portion of pro-brain natriuretic peptide
(NT-proBNP) appears to be a more reliable postmortem tool
than the BNP, owing to its longer half-life and greater
stability. In living persons, NT-proBNP is considered to be a
marker of heart failure, and its level rises after cardiac
ischemia. The goal of this study was first to evaluate the
postmortem stability of NT-proBNP, then to measure the NT-
proBNP levels in postmortem cases of heart failure related to
coronary ischemia. The goal of this study was also to
evaluate the correlations between different specimens col-
lected at autopsy (e.g. blood, serum, vitreous humor and
pericardial fluid). The study included 96 cases, which were
classified into 4 groups according to the autopsy and
histological findings. The NT-proBNP levels were signifi-
cantly higher in individuals who had suffered from chronic
cardiac ischemia, with or without acute coronary events, than
in either control cases or those who had suffered from acute
thromboembolism or acute rupture of a plaque without
chronic cardiac ischemia. The highest levels were registered
in individuals who had suffered from acute coronary
thromboembolism in association with chronic coronary
ischemia. Good correlations in the NT-proBNP levels for
the different specimens were observed between samples of
femoral blood, serum, and pericardial fluid. Our data
indicated that postmortem measurements of NT-proBNP are
reliable and compatible with clinical findings.
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Introduction
Acute heart failure is the most common cause of hospital-
ization and death in Europe, especially in elderly individuals
[1]. In most clinical cases, heart failure is a consequence of
cardiovascular disease. However, in medicolegal situations,
heart failure may be attributable to other causes, and its
identification could have important legal implications [2–8].
It could be associated with acute disease or trauma, with
drug intoxication or a protracted state of agony.
In clinical medicine, acute heart failure is diagnosed
primarily on the basis of clinical symptoms. Nevertheless,
biochemical markers are very useful tools in diagnosis as well
as in assessing risk factors and therapeutic decision making [9–
11]. In forensic medicine, the diagnosis of heart failure is more
difficult. It is impossible to detect the usual clinical symptoms,
and in many cases, the autopsy findings are nonspecific for
the diagnosis of heart failure. The usual postmortem signs of
heart failure include cardiac dilatation and visceral congestion
of the internal organs. But, these features are difficult to assess
objectively, especially after a long postmortem period.
Int J Legal Med (2008) 122:415–420
DOI 10.1007/s00414-008-0257-z
K. Michaud (*) :M. Augsburger : S. Sabatasso :M. Bollmann :
P. Mangin
Centre Universitaire romand de Médecine Légale,
Centre Hospitalier Universitaire Vaudois, University of Lausanne,
Bugnon 21,
1005 Lausanne, Switzerland
e-mail: katarzyna.michaud@chuv.ch
N. Donzé
Institut Cantonal des Hôpitaux Valaisans,
Grand Champsec 86,
1950 Sion, Switzerland
M. Faouzi
Centre d’épidémiologie clinique,
Centre Hospitalier Universitaire Vaudois, University of Lausanne,
Bugnon 17,
1005 Lausanne, Switzerland
Clinical biochemical markers of cardiac function have
also been monitored postmortem. However, for many
markers, such as troponin, the postmortem analyses are
unreliable or controversial [12, 13]. The natriuretic pep-
tides, especially the aminoterminal portion of pro-brain
natriuretic peptide (NT-proBNP), have recently been intro-
duced as biomarkers of cardiac function. BNP and NT-
proBNP are neurohormones, synthesized primarily by atrial
or ventricular myocardial cells. These neurohormones are
released from cardiac myocytes in response to ventricular
wall stress, ischemia, or infarction. The biological effects of
BNP include diuresis, vasodilatation, and inhibition of
rennin and aldosteron production and of cardiac and
vascular myocytes growth. Whether NT-proBNP has
biological effects on its own is currently unknown [14].
BNP and NT-proBNP differ in their biochemical and
physiological characteristics [15–17]. BNP is hormonally
active, with a half-life of approximately 22 min, whereas
NT-proBNP, the inactive precursor of BNP, lacks a
clearance receptor and, therefore, has a longer half-life
(about 120 min). The circulating concentration of NT-
proBNP is believed to be less susceptible to the condition
under which the blood sample is taken [18]. In addition,
NT-proBNP appears to be more discerning marker of early
cardiac dysfunction than BNP [16, 19]. The goal of this
preliminary study was to evaluate the possibility of
measuring NT-proBNP postmortem. To this end, we
evaluated first the postmortem stability of NT-proBNP.
Then, in order to control the correlation with clinical
observation, we monitored the NT-proBNP levels in cases
of sudden cardiac death which were clinically attributed to
heart failure from coronary ischemia and in control cases
without cardiac pathology. The last goal of this study was
to compare the correlations of levels of NT-proBNP within
different specimens (blood, serum, vitreous humor, and
pericardial fluid) that were collected during the autopsies.
Materials and methods
A total of 96 cases (73 males and 23 females) were selected
from forensic autopsies that had been performed between
2002 and 2006. The age of the persons ranged from 31 to
90 years at death. The estimated postmortem period did not
exceed 24 h. In each case, the autopsy was followed by a
histological examination. Cases of liver or kidney failure
were excluded from the study. Examination of the heart had
involved macroscopical inspection and a histological
analysis of myocardial specimens that had been derived
from at least five different topographic locations, namely
left anterior, left lateral, left posterior, septal, and right lateral.
The sections were routinely stained with hematoxyline–eosin.
In 56 cases, signs of acute or chronic cardiac ischemia were
identified. In the cases of acute cardiac ischemia, there was
evidence of either acute coronary thromboembolism or acute
plaque rupture. The criteria for chronic ischaemic heart
disease included pathology of the coronary artery with a
significant degree of atherosclerotic stenosis (more than 75%)
and histopathologic changes in myocardium (e.g., fibrotic
foci). The 40 control cases included deaths due to noncardiac
causes with neither macroscopical nor microscopical signs of
coronary ischemia.
According to the medical records and the autopsy
findings, the cases were classified into four groups:
Group A: Acute coronary thromboembolism or acute
plaque rupture without evidence of chronic
cardiac ischemia (n=18),
Group B: Acute coronary thromboembolism or acute
plaque rupture in association with chronic
coronary ischemia (n=13),
Group C: Chronic cardiac ischemia without acute coronary
events (n=25),
Group D: Control cases, attributed to noncardiac causes
with no signs of cardiac ischemia (n=40).
Ages and sex of cases are detailed in Table 1.
In groups A and B, the cause of death was attributable to
coronary ischemia, in group C, 17 deaths (68%) were
attributable to coronary ischemia, two to gunshot lesions,
three to trauma, two to carbon monoxide intoxication, and
one to stabbing.
In the control group, the causes of death were gunshot
lesions in 16 cases, trauma in 18, and asphyxia in six
(hanging in five cases and drowning in one).
Femoral blood, serum, vitreous humor and pericardial
fluid were collected during the autopsy. Serum was derived
Table 1 Levels of NT-proBNP [mean value ± SD (pg/mL)]
Groups Number Male/
female
Age
range
Age
(years)
Heart
weight
Serum Femoral
blood
Vitreous
fluid
Pericardial
fluid
A (acute coronary ischemia) 18 18/0 31–59 48±10 431±65 108±156 28±36 183±138 1756±1718
B (acute and chronic coronary
ischemia)
13 9/4 47–86 62±13 439±88 688±309 536±310 323±217 18070±12596
C (chronic coronary ischemia) 25 20/5 33–90 62±14 486±144 310±294 238±198 288±301 5441±4408
D (control) 40 30/10 18–72 39±14 344±81 68±64 33±30 168±147 1236±1492
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from a blood sample, which was centrifuged immediately
after collection. Postmortem specimens were stored at −20°C
until the time of analysis.
To evaluate the stability of NT-proBNP in postmortem
blood, one sample was divided into three groups of five
aliquots, which were analyzed on days 0, 3, 9, 15, and 24.
The first group of aliquots was maintained at ambient
temperature, the second group at +4°C, and the third group
at −20°C. A similar experimental set-up was established for
the samples of pericardial fluid sample from the same case.
The concentration of NT-proBNP was measured using a
chemiluminescent immunoassay kit (Elecsys 2010 analyser,
Roche Diagnostics, Basel, Switzerland; Dimension Xpand
plus, Dade Behring, Deerfield, IL, USA).
The data obtained from groups A–D were statistically
analyzed using nonparametric Mann–Whitney test. The
correlations between sets of data were evaluated using
Spearman’s correlation test.
Results
Stability of NT-proBNP within postmortem samples
of blood and pericardial fluid
Data pertaining to the stability of NT-proBNP within
postmortem samples of blood and pericardial fluid that
had been stored at different temperature for 24 h are
presented in Fig. 1. At ambient temperature, NT-proBNP
underwent substantial degradation within both body fluids
during the course of 24 days (50% in blood and 37% in
pericardial fluid). Within blood samples, NT-proBNP was
less prone to degradation at −20°C than at 4°C, but within
samples of pericardial fluid, the rate of degradation of NT-
proBNP was similar at −20°C and at 4°C. After 24 days,
only 16% of the NT-proBNP had been degraded.
NT-proBNP levels in the different groups and bodily fluids
Within samples of blood, serum, and pericardial fluid, the
levels of NT-proBNP were significantly higher (p<0.001) in
individuals who had suffered from chronic cardiac ischemia,
with or without acute coronary events (groups B and C), than
in either control persons (group D) or those who had suffered
from acute coronary thromboembolism or acute rupturing of
a plaque without chronic cardiac ischemia (group A).
The highest values were registered in individuals who
had suffered from acute coronary thromboembolism in
association with chronic coronary ischemia (group B).
Within samples of the vitreous humor, the differences
between the groups were not significant (p>0.05; Fig. 2,
Tables 1 and 2).
The most striking correlations in the levels of NT-proBNP
for the different groups were observed between blood and
pericardial fluid (r=0.73), between blood and serum (r=
0.77), and between serum and pericardial fluid (r=0.65). The
correlations between vitreous humor and blood (r=0.17),
between vitreous humor and serum (r=0.11), and between
vitreous humor and pericardial fluid (r=0.21) were weak.
Dependency of NT-proBNP levels on gender, age and heart
weight
To ascertain whether the levels of NT-proBNP within the
different bodily fluids were linked with gender, age, and
heart weight, a logistic regression model was applied. The
odds ratios and p values are presented in Table 3. In the
multivariable analysis for blood samples, only age (odds
ratio=1.006; p=0.036) and heart weight (odds ratio=1.065;
p=0.002) were significantly associated with higher levels
of NT-proBNP.
The logistic regression analysis revealed that blood
levels of NT-proBNP rose significantly with an increase
in heart weight (odds ratio=1.00; p=0.004) and with an
increase in age (odds ratio=1.072; p<0.0001). Similar
results were obtained for the levels of NT-proBNP within
the serum, pericardial fluid, and vitreous humor. Only
within the vitreous humor samples were the levels of NT-
proBNP significantly different between males and females
(odds ratio=4.54; p=0.007).
The age distribution between the four groups differed
significantly, except between groups A and D (p=0.105).
The heart weight distribution between the four groups
likewise differed significantly (p<0.001).
Discussion
The postmortem levels of natriuretic peptides have been
measured in only a few studies. Zhu et al. [20] attributed
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Fig. 1 Stability of NT-proBNP within postmortem samples of blood
and pericardial fluid
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elevation in the postmortem pericardial levels of the atrial
natriuretic peptide and the BNP to acute atrial overload and
subacute or chronic heart failure, respectively. However, in
our opinion, BNP is not suitable for forensic practice. In our
experience, BNP cannot be detected in frozen postmortem
samples (data not presented). This is not surprising since
Mueller et al. have indeed questioned the validity of
endogenous BNP measurement in frozen samples [21]. On
the basis of our own experience with BNP, and in accordance
with published data, we conjectured that for autopsic
purposes, NT-proBNP might be a more reliable biomarker
than BNP, owing to its greater stability and longer half-life
reported in the literature [17, 22–24].
Plasma biomarkers can be very useful diagnostic tools if
measurement is reliable. Hence, it is necessary to ascertain
whether NT-proBNP decays appreciably during the storage
Table 2 Results of the inter-group analysis using Wilcoxon’s two-sample, rank-sum (Mann Whitney) test
Groups Blood Serum Pericardial fluid Vitreous fluid
A B <0.0001 (s) <0.0001 (s) 0.0005 (s) 0.0647 (ns)
A B + C <0.0001 (s) <0.0001 (s) 0.0002 (s) 0.3703 (ns)
A D 0.7967 (ns) 0.9029 (ns) 0.1303 (ns) 0.2644 (ns)
B + C D <0.0001 (s) <0.0001 (s) <0.0001 (s) 0.0385 (s)
B C 0.0031 (s) 0.0021 (s) 0.0406 (s) 0.2758 (ns)
A + B + C D <0.0001 (s) 0.0005 (s) <0.0001 (s) 0.0370 (s)
s Significant, ns nonsignificant
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Fig. 2 NT-proBNP levels within different bodily fluids (blood, serum, pericardial fluid, and vitreous humor)
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of postmortem samples. Using clinical samples of serum
and plasma, Nowatzke et al. demonstrated that NT-proBNP
remains stable for at least 1 year at sub-zero temperature
[24]. Our own data partially support these findings. After
24 days of storage at −20°C, the concentration of NT-
proBNP in samples of pericardial fluid decreased by no
more than 16%. In clinical labolatory practice, only serum
NT-proBNP levels are measurable. In forensic practice, in
many cases, serum might be unavailable especially in cases
of trauma or in decomposed bodies. Therefore, it was
important to establish the correlations between serum and
other body fluids. In this study, good correlations in the NT-
proBNP levels for the different groups were observed
between samples of serum, blood, and pericardial fluid.
Hence, any of these body fluids could be used for
postmortem testing. The levels of NT-proBNP in samples
of the vitreous humor did not correlate well with those in
the other body fluids. A possible explanation for this
discrepancy may lie in the existence of the blood-aqueous
barrier [25, 26].
In this study, individuals who had suffered chronic
cardiac ischemia, with or without acute coronary events
(group B and C), had significantly higher levels of NT-
proBNP than either control persons (group D) or those who
had suffered from acute coronary thromboembolism or
acute rupturing of plaques without chronic cardiac ischemia
(group A). The highest levels were registered in individuals
who had suffered from acute coronary thromboembolism in
association with chronic cardiac ischemia (group B).
According to the literature, in patients with an acute
coronary syndrome, the levels of NT-proBNP rise rapidly,
with an initial peak after 12–48 h and a second one after 5–
8 days [27].
The lower levels of NT-proBNP in cases of acute
coronary thromboembolism (group A) could be accounted
for by the short time elapsing between the formation of the
thrombus and death, which intervened before the first peak
in NT-proBNP had been attained. As mentioned, individ-
uals who had suffered from acute coronary thromboembo-
lism in association with chronic coronary ischemia (group
B) had the highest levels of NT-proBNP. This finding
suggests that the existence of chronic coronary ischemia
promotes a more rapid and augmented release of NT-
proBNP in the event of an acute coronary thromboembo-
lism. The augmented releases of NT-proBNP may reflect an
increase in gene expression, as suggested for BNP [28]. In
clinical practice, high levels of NT-proBNP, which are
associated with cardiac diseases in general and with acute
coronary syndromes and heart failure in particular, have a
poor prognostic value [11, 27, 29–32]. Our own data accord
with clinical observations.
In this study, the higher levels of NT-proBNP were
correlated to an increase in heart weight. This is not
surprising, as heart failure may be associated with an
increase in heart weight. The correlation between increase
of NT-proBNP levels with an increase in age is compatible
with published clinical studies.
In conclusion, the accordance between clinical observa-
tions, histopathological findings, and postmortem levels of
NT-proBNP within femoral blood, serum, and pericardial
fluid indicate that this biomarker of cardiac function could
be of diagnostic value in forensic medicine, albeit that it is
not helpful in detecting early myocardial ischemia. The
postmortem measurement of NT-proBNP could be service-
able in many medicolegal situations, not only in those in
which cardiovascular pathology is implicated.
Study limitations
The number of cases included in this study was fairly small.
Nevertheless, our preliminary data are so encouraging as to
justify further postmortem investigations of a similar kind
with larger cohorts.
Table 3 Results of the logistic
regression analysis Outcome Indep-var Odds ratio P value
Blood Sex 0.49 0.23
Blood Age 1.072 <0.001
Blood Heart weight 1.007 <0.001
Serum Sex 0.47 0.17
Serum Age 1.06 0.004
Serum Heart weight 1.004 0.049
Pericardial Fluid Age 1.10 <0.001
Pericardial Fluid Sex 0.41 0.14
Pericardial Fluid Heart weight 1.005 0.058
Vitreous Fluid Age 1.002 0.89
Vitreous Fluid Sex 4.55 0.007
Vitreous Fluid Heart weight 1.007 0.008
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